Lucid Diagnostics Quick Ratio

What does Lucid Diagnostics do? Lucid Diagnostics, Inc. generates revenue through its commercial-stage medical diagnostics technology focused on patients with gastroesophageal reflux disease (GERD). The company markets EsoGuard, a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells, and EsoCheck, a noninvasive swallowable balloon capsule catheter device used to sample these cells in office procedures. These products address the progression from chronic heartburn to esophageal precancer and lethal esophageal adenocarcinoma (EAC). The EsoCheck device consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter, featuring a soft silicone balloon with textured ridges that swab surface esophageal cells. This sampling capability enables the subsequent application of the EsoGuard assay. The company also develops EsoCure, an esophageal ablation device intended to treat dysplastic BE before it progresses to EAC, thereby expanding its therapeutic offerings within the segment of patients suffering from reflux-related conditions. Lucid Diagnostics is one of the most popular companies on Eulerpool.